Recruiting
Phase 1
Phase 2

LCB02A

Sponsor:

LigaChem Biosciences, Inc.

Code:

NCT07460375

Conditions

Advanced Solid Tumors

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

LCB02A

Study Details

Brief summary:

This is a Phase 1/2 open label study consisting of dose escalation cohorts (Phase 1) followed by expansion cohorts (Phase 2). The Phase 1 dose escalation population includes subjects with advanced solid tumors that are refractory to standard of care therapy or for whom no standard of care options are available. Once the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of single agent LCB02A is determined, the study will proceed to Phase 2 expansion cohorts in selected tumor types.

Conditions

Advanced Solid Tumors

Study ID

NCT07460375

Start date

Oct 14, 2026

Status verified date

Oct, 2026

Completion date

Aug, 2030

Anticipated

Primary completion date

Feb, 2030

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Key Inclusion Criteria:

  • Phase 1 Dose Escalation: histologically or cytologically confirmed advanced solid tumors that are Claudin 18.2 positive and refractory to standard of care treatment.
  • Phase 2 Dose Expansion: selected histologically or cytologically confirmed advanced solid tumors that are Claudin 18.2 positive and refractory to standard of care treatment. Expansion cohort indications will be prioritized based on data from the Phase 1 dose escalation portion.
  • Prior treatment with Claudin 18.2 directed therapy is permitted.
  • Measurable disease as defined by RECIST v1.1
  • Willingness to provide archival tumor tissue when available, or to undergo a pre-treatment biopsy if archival tissue is not available.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Adequate organ function as defined by:

  • Absolute neutrophil count ≥ 1.5 × 109/L , without colony stimulating factor support for the past 14 days
  • Platelet count ≥ 100 × 109/L
  • Hemoglobin level ≥ 9.0 g/dL
  • Total bilirubin ≤ 1.5× upper limit of normal (ULN) or <3 x ULN with Gilbert's syndrome or liver metastases at baseline
  • Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 2.5× ULN (≤ 5.0× ULN for subjects with liver metastases)
  • Albumin ≥ 2.5 g/dL
  • Creatinine clearance ≥ 60 mL/min

Key Exclusion Criteria:

  • Prior exposure to ADCs with a Topo1 inhibitor payload.
  • Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.

Note: Patients may be considered for enrollment if they have previously treated brain metastases that are clinically stable or radiologically stable for at least 14 days prior to the first dose.

  • Received radiotherapy within 21 days prior to the first dose of study drug. Note: For palliative radiotherapy for symptomatic improvement of non-central nervous system (CNS) lesions (total duration of radiotherapy ≤ 14 days), a radiation washout period of 7 days is required prior to the first dose.
  • Any medical conditions that may confound the study results, interfere with the patient's compliance, or impair the interests of the subject, as assessed by the Investigator.

Study Design

Enrollment

191 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: LCB02A monotherapy

Interventions

LCB02A

CLDN18.2-directed human monoclonal antibody (Ab) linked to a topoisomerase I inhibiting payload.

Primary outcome measure

  • Safety of LCB02A (Phase 1 and 2) [ Time Frame: Up to 48 months ]
  • Recommended Phase 2 dose of LCB02A (Phase 1) [ Time Frame: Up to 24 months ]
  • Objective response rate (Phase 2) [ Time Frame: Up to 24 months ]

Central Contacts and Locations

Central contacts

David Browning

+1-615-975-7776clinicaltrials@ligachembio.com

Locations

START New York - Long Island

Recruiting

Lake Success, New York, United States, 11042

Principal Investigator:

Geraldine O'Sullivan Coyne, MD

Princess Margaret Hospital

Recruiting

Toronto, Ontario, Canada, M5S 3H2

Principal Investigator:

Erica Tsang, MD

More Information

Sponsor

LigaChem Biosciences, Inc.

Last update posted

Oct 19, 2026

Last verified

Oct, 2026

Keywords

  • Claudin 18.2
  • CLDN18.2

Trial information was received from ClinicalTrials.gov and was last updated on 2026-10-24. This information was provided to ClinicalTrials.gov by LigaChem Biosciences, Inc. on 2026-10-19. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.